Cyclophosphamide

Catalog No.S1217 Batch:S121704

Print

Technical Data

Formula

C7H15Cl2N2O2P
Molecular Weight 261.09 CAS No. 50-18-0
Solubility (25°C)* In vitro DMSO 52 mg/mL (199.16 mM)
Water 52 mg/mL (199.16 mM)
Ethanol 52 mg/mL (199.16 mM)
In vivo (Add solvents to the product individually and in order)
Clear solution
5% DMSO 95% Corn oil
0.65mg/ml Taking the 1 mL working solution as an example, add 50 μL of 13 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
2.6mg/ml Taking the 1 mL working solution as an example, add 50 μL of 52 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Cyclophosphamide(NSC 26271,Endoxan, Cytoxan, Neosar, Procytox, Revimmune, Cytophosphane) is a nitrogen mustard alkylating agent from the oxazophorines group.
Targets
DNA replication [1]
In vivo

Cyclophosphamide is an alkylating agent with cytotoxic and immunosuppressive activities. Cyclophosphamide requires enzymatic and chemical activation to release active phosphoramide mustard which produces the interstrand and intrastrand DNA crosslinks at guanine N-7 positions. Cyclophosphamide exerts its cytotoxic activity by inhibiting nuclear DNA replication. The mechanism of Cyclophosphamide -induced immunosuppression is possibly due to direct cytotoxic effect of the drug on immunocompetent lymphocytes, particulafly those that have undergone antigenic differentiation and division. Cyclophosphamide has its greatest effect on B cells with relative T cell-sparing effect. [1] Trials in various tumor-bearing animals confirmed this in vivo activity and demonstrated fairly potent antitumor effect. Cyclophosphamide, in combination with other antineoplastic agents, is used for the treatment of various cancers, including breast, lymphoid and pediatric malignancies. [2]

Protocol (from reference)

Customer Product Validation

Data from [Data independently produced by Cancer Res, 2012, 72(23):6200-8]

Selleck's Cyclophosphamide has been cited by 10 publications

Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host [ J Immunother, 2024, 10.1097/CJI.0000000000000505] PubMed: 38270462
Exploring miRNA‑target gene profiles associated with drug resistance in patients with breast cancer receiving neoadjuvant chemotherapy [ Oncol Lett, 2024, 27(4):158] PubMed: 38426156
ATR/Chk1 interacting lncRNA modulates DNA damage response to induce breast cancer chemoresistance [ Cell Insight, 2024, 3(5):100183] PubMed: 39148723
Adipose-derived stem cells promote the repair of chemotherapy-induced premature ovarian failure by inhibiting granulosa cells apoptosis and senescence [ Stem Cell Res Ther, 2023, 14(1):75] PubMed: 37038203
PTC596-Induced BMI-1 Inhibition Fights Neuroblastoma Multidrug Resistance by Inducing Ferroptosis [ Antioxidants (Basel), 2023, 13(1)3] PubMed: 38275623
Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy [ Neoplasia, 2023, 10.1016/j.neo.2023.100949] PubMed: 37956532
Novel model of triple-negative breast cancer produces viable circulating tumor cells and rapid lung metastasis for functional testing in vivo [ Neoplasma, 2023, 10.4149/neo_2023_230404N185] PubMed: 37789779
Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents [ BMC Pregnancy Childbirth, 2023, 23(1):151] PubMed: 36890528
Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents [ BMC Pregnancy Childbirth, 2023, 23(1):151] PubMed: 36890528
Targeting Sonic Hedgehog-Associated Medulloblastoma through Inhibition of Aurora and Polo-like Kinases. [Markant SL, et al. Cancer Res, 2013, 73(20):6310-22] PubMed: 24067506

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.